Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company completes acquisition of Versanis Bio
Lilly signed the definitive agreement to acquire Versanis Bio in July this year. At the time of the deal announcement, its terms specified that shareholders of Versanis were
Lilly signed the definitive agreement to acquire Versanis Bio in July this year. At the time of the deal announcement, its terms specified that shareholders of Versanis were
Stockholders of Chinook will receive $40.00 in cash per share, a total of $3.2bn, from Novartis. Upon achieving certain regulatory milestones, they will further receive $4.00 in cash
In June this year, the therapy, in combination with Genentech’s Tecentriq received FDA fast track designation (FTD) for the treatment of extensive-stage small cell lung cancer (ES-SCLC) patients.
The expansion involved addition of one 50L, two 200L, and two 1,000L suspension single-use bioreactors. It also offers the flexibility to accommodate up to four iCellis500 adherent single-use
The agreement for VAZKEPA capsules comes after approval from Israel’s Ministry of Health (MOH) Pharmaceuticals Division. The approval of these capsules has been granted for reducing cardiovascular events
The subsidiary, Daiichi Sankyo RD Novare (RD Novare), with nearly 400 employees was initially named as Daiichi Sankyo RD Associe in 2006 and was changed to the current
Said to be the first and only oral, once-a-day, 14-day treatment, ZURZUVAE can provide quick improvements in depressive symptoms for women with PPD. Shortly after scheduling as a
As per the terms of the exclusive worldwide agreement, Agios will acquire the rights to develop and market Alnylam’s preclinical candidate that targets TMPRSS6, a key driver of
The company received the patent from the European Patent Office. The drug is being assessed in the ongoing Phase III programme CONCLUDE for treating patients with moderate to
Co-led by Santé Ventures and Longwood, the financing round has seen participation from Alexandria Venture Investments, Astellas Venture Management, and DCVC Bio. Solu Therapeutics’ CyTaC platform has been